---
title: "MetaVia Inc. (MTVA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MTVA.US.md"
symbol: "MTVA.US"
name: "MetaVia Inc."
industry: "Biotechnology"
datetime: "2026-05-19T20:27:20.933Z"
locales:
  - [en](https://longbridge.com/en/quote/MTVA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MTVA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MTVA.US.md)
---

# MetaVia Inc. (MTVA.US)

## Company Overview

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.metaviatx.com](https://www.metaviatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.43 | 128 | - | - | - |
| PB | 0.62 | 51 | 3.01 | 2.37 | 0.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.88 |
| Highest Target | 30.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MTVA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MTVA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MTVA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MTVA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**